Research

Estimating Minimally Important Differences for the Worst Pain Rating of the Brief Pain Inventory–Short Form


 

Conflicts of interest: This research was funded by Amgen Inc., Thousand Oaks, CA in part through a contract to Health Outcomes Solutions. SDM and RDC were paid by Health Outcomes Solutions, and YQ, QJ, RD and KC are employees of Amgen and own Amgen stock and stock options.

Correspondence to: Susan D. Mathias, Health Outcomes Solutions, PO Box 2343, Winter Park, FL 32790; telephone: (407) 643-9016; fax: (866) 384-0194


1 PubMed ID in brackets

Pages

Recommended Reading

Financial Worries Top Psychosocial Concern of Cancer Patients
MDedge Hematology and Oncology
Imaging Recommendations Largely Ignored in Prostate Cancer
MDedge Hematology and Oncology
Improving Access to Pediatric Palliative Care
MDedge Hematology and Oncology
Rising Cancer Survivorship Rates Spark Research Need
MDedge Hematology and Oncology
Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial
MDedge Hematology and Oncology
Transition to Survivor Care Requires Link to Community Physicians
MDedge Hematology and Oncology
EGFR Status May Explain Depression-Survival Link in NSCLC
MDedge Hematology and Oncology
Young Adults Suffer More Cancer Pain, Distress
MDedge Hematology and Oncology
Study Finds Few Second Cancers Attributable to Radiotherapy
MDedge Hematology and Oncology
Management of hyperuricemia in adults with or at risk of tumor lysis syndrome
MDedge Hematology and Oncology